Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 May;24(3):237-48.
doi: 10.1023/B:JOCI.0000025445.21894.e5.

Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations

Affiliations

Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations

Hiroshi Kato et al. J Clin Immunol. 2004 May.

Abstract

OX40/OX40 ligand (OX40L) interactions are implicated in costimulation for both CD4(+) T and B cells in a bidirectional manner. To determine the role of OX40/OX40L interactions in recipient antidonor responses after multiple allogeneic transfusions, we examined alloreactive cytotoxic T lymphocyte (allo-CTL) activity and alloantibody production in repeatedly alloimmunized OX40L-deficient mice. After the fifth alloimmunization, whereas OX40L-deficient mice showed allo-CTL activity with levels comparable to those of wild-type mice, alloantibody production in OX40L-deficient mice was significantly reduced, accompanied by fewer memory B and CD4(+) T cells with reduced function. Furthermore, nu/nu mice that received OX40L-deficient T cells still exhibited impaired alloantibody production with fewer memory CD4(+) T and B cells. In contrast, RAG-2-deficient mice that received both wild-type T cells and OX40L-deficient B cells produced scant alloantibodies with fewer memory B cells, but sufficient memory CD4(+) T cells. Thus, OX40L on B cells, rather than on T cells, is apparently required for adequate and persistent production of alloantibodies after repeated alloimmunizations.

PubMed Disclaimer

References

    1. Blood. 1995 Jul 15;86(2):805-12 - PubMed
    1. Blood. 1988 Sep;72(3):964-9 - PubMed
    1. J Immunol. 1999 Sep 15;163(6):3007-11 - PubMed
    1. Blood. 1998 Nov 1;92(9):3338-45 - PubMed
    1. J Immunol. 1998 Dec 15;161(12):6510-7 - PubMed

Publication types

LinkOut - more resources